This article was originally published in The Gray Sheet
Executive SummaryCompany exits cardiovascular market Aug. 1 via sale of its AngioDynamics Ltd. interventional cardiology business to management, supported by the venture capital firms Alliance Investment Capital and ICC. The deal includes the division's Enniscorthy, Ireland manufacturing facility for electromechanical injectors and sterile, disposable devices. The move is in line with the parent firm's strategy to focus entirely on the interventional radiology market
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.